Temozolomide in the treatment of recurrent malignant glioma

Options for chemotherapy at the time of recurrence in patients with malignant glioma are limited. The authors describe the efficacy and safety results of their institution's open‐label, compassionate‐use protocol of temozolomide for patients with recurrent malignant glioma.

[1]  H. Hirschberg,et al.  Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. , 1992, Neurosurgery.

[2]  O. De Witte,et al.  Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine , 1998, Journal of Neuro-Oncology.

[3]  Reto Meuli,et al.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Kennard,et al.  Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. , 1993, European journal of cancer.

[5]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W. Yung,et al.  Intravenous carboplatin for recurrent malignant glioma: a phase II study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Graham.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[8]  N. Bleehen,et al.  A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. , 1991, British Journal of Cancer.

[9]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[10]  A. Brandes,et al.  Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study , 2002, Oncology.

[11]  H. Friedman.  Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. , 2000, Seminars in Oncology.

[12]  L. Junck,et al.  Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure , 1990, Neurology.

[13]  M. Prados,et al.  Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors , 1989, Cancer.

[14]  B. Scheithauer,et al.  Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Yung.  Temozolomide in malignant gliomas. , 2000, Seminars in oncology.

[16]  K. Hess,et al.  Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Hatlevoll,et al.  Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study group , 1981, Cancer.

[18]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[19]  D P Byar,et al.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.

[20]  S. Ashley,et al.  Temozolomide as Second-line Chemotherapy for Relapsed Gliomas , 2002, Journal of Neuro-Oncology.

[21]  R. McLendon,et al.  DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  N. Bleehen,et al.  Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma , 1997, Cancer Chemotherapy and Pharmacology.

[23]  W. Yung,et al.  Intravenous BCNU and AZQ in patients with recurrent malignant gliomas , 1989, Journal of Neuro-Oncology.

[24]  A. Brandes,et al.  Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas , 1997 .

[25]  D. Schoenfeld,et al.  Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study , 1983, Cancer.

[26]  E. Newlands,et al.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). , 1992, British Journal of Cancer.

[27]  M. Prados,et al.  New chemotherapy options for the treatment of malignant gliomas. , 1999, Current opinion in oncology.

[28]  P. Gutin,et al.  Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. , 1990, International journal of radiation oncology, biology, physics.

[29]  M. Prados,et al.  Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study , 1997, Journal of Neuro-Oncology.

[30]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[31]  R. McLendon,et al.  Irinotecan therapy in adults with recurrent or progressive malignant glioma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[33]  J. Raizer,et al.  A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. , 2002, Neuro-oncology.